• Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancers
• U.S. study to investigate Veyonda + doxorubicin in sarcomas
• CEP-2 target start Q4 2019
• Comprehensive plan on track to establish Veyonda as key, versatile cancer drug
SYDNEY, April 10, 2019: Noxopharm Ltd (ASX:NOX) (Noxopharm or the ‘Company’) provides an update on the progress of its Veyonda chemotherapy enhancement program (CEP) which is being run in parallel to the Company’s two radio-enhancing programs (DARRT and LuPIN). The three programs collectively are investigating the unique dual cytotoxic and immuno-oncologic properties of Veyonda, with CEP exploring using these properties in combination with standard chemotherapy to achieve anti-cancer effects in patients with end-stage, metastatic solid cancers. Together these programs aim to cement Veyonda as a key, versatile treatment in the multi-billion dollar cancer market.
For further information please download PDF attached:
Download this document
